Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Pilot Study of ADP-A2M4 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Cancer

NCT04408898 is registered in ClinicalTrials.gov with Adaptimmune as lead sponsor.

NCT NCT04408898
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04408898 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Pilot Study of ADP-A2M4 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Cancer
Lead sponsor
Adaptimmune
Phase
Phase 2
Overall status
Withdrawn
Start date
July 2, 2020
Completion date
December 31, 2021
Enrollment
0 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer